Gallus Acquiring FlexFactory® Bioproduction Lines and Single-Use Bioreactors; Xcellerex Partners to Help Customers Gain Access to Commercial Biomanufacturing Facility MARLBOROUGH, Mass. & ST.

MARLBOROUGH, Mass., Aug 26, 2010 (BUSINESS WIRE) -- Xcellerex, Inc. announced today that it has signed a memorandum of understanding with SK Chemicals, Co., Ltd., one of South Korea's largest ...

Xcellerex will leverage its XDR bioreactors and FlexFactory platform to allow future scale-up. Xcellerex and Humacyte signed a collaboration agreement under which Xcellerex will develop a single-use ...

Xcellerex, Inc. and Itero Biopharmaceuticals, Inc. announced today that they have signed a Letter of Intent to enter into a strategic collaboration for the production of Itero's lead product, an ...

MARLBOROUGH, Mass.--(BUSINESS WIRE)--Xcellerex, Inc. announced today that Guy Broadbent has been appointed President and Chief Executive Officer and a member of the company’s board of directors. Mr.

Xcellerex, Inc. received two Phase-I contracts from the Defense Advanced Research Projects Agency (Arlington, VA) for the Accelerated Manufacture of Pharmaceuticals program. Phase I of the AMP program ...

MARLBOROUGH, Mass.--(BUSINESS WIRE)--Xcellerex, Inc., which provides next generation manufacturing services and systems for biotherapeutics and vaccines based on proprietary, single use, disposable ...

Xcellerex is revolutionizing the way biomolecules are developed, manufactured, and commercialized. The company’s unique single-use technology platform transforms biomanufacturing economics, enabling ...

On Mar. 7, 2012, GE Healthcare announced an agreement to acquire Xcellerex, a supplier of manufacturing technologies for the biopharmaceutical industry, for an undisclosed amount. On Mar. 7, 2012, GE ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Xcellerex Inc. has begun building its cGMP FlexFactory ...